Design and Sample Size Considerations for Simultaneous Global Drug Development Program
暂无分享,去创建一个
[1] Hui Quan,et al. Sample size considerations for Japanese patients in a multi‐regional trial based on MHLW guidance , 2009, Pharmaceutical statistics.
[2] Shein-Chung Chow,et al. ASSESSING SENSITIVITY AND SIMILARITY IN BRIDGING STUDIES , 2002, Journal of biopharmaceutical statistics.
[3] D. DeMets,et al. Increasing the sample size when the unblinded interim result is promising , 2004, Statistics in medicine.
[4] K. K. Lan,et al. Further Comments on the Alpha-Spending Function , 2009 .
[5] K. K. Lan,et al. A Short Note on Sample Size Estimation , 2009 .
[6] Somesh Chattopadhyay,et al. Statistical Monitoring of Clinical Trials: A Unified Approach , 2008 .
[7] W. Shih,et al. Clinical trials for drug registrations in Asian-Pacific countries: proposal for a new paradigm from a statistical perspective. , 2001, Controlled clinical trials.
[8] Chin-Fu Hsiao,et al. A Group Sequential Approach to Evaluation of Bridging Studies , 2003, Journal of biopharmaceutical statistics.
[9] Michael R. Chernick,et al. Statistical Monitoring of Clinical Trials: a Unified Approach , 2007, Technometrics.
[10] Y. Soo,et al. The Use of Weighted Z-Tests in Medical Research , 2005, Journal of biopharmaceutical statistics.
[11] Chin-Fu Hsiao,et al. A TWO-STAGE DESIGN FOR BRIDGING STUDIES , 2004, Journal of biopharmaceutical statistics.